APA (7th ed.) Citation

G, G., FG, H., K, S., GC, I., J, S., L, M., . . . H, K. (2023). Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clinical lymphoma, myeloma & leukemia, 23(10), 742. https://doi.org/10.1016/j.clml.2023.05.009

Chicago Style (17th ed.) Citation

G, Gener-Ricos, et al. "Low-Dose Dasatinib (50 Mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results." Clinical Lymphoma, Myeloma & Leukemia 23, no. 10 (2023): 742. https://doi.org/10.1016/j.clml.2023.05.009.

MLA (9th ed.) Citation

G, Gener-Ricos, et al. "Low-Dose Dasatinib (50 Mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results." Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. 10, 2023, p. 742, https://doi.org/10.1016/j.clml.2023.05.009.